Acronym ILA VAX
Category
Marine Biotechnology
Title ILA vaccine and establishment of technology platform for viral vaccines Programme National Programme
Instrument (FP6)
Contact Type (FP7)
Strand (Interreg)
NA
Theme (FP7)
Activity Area (FP6)
Regional Area (Interreg)
Action (COST)
NA
Specific Programme (FP7)
NA
Funding source National Coordinator Espen Rimstad Coordinator email espen.rimstad@nmbu.no
Coordinator institution
NMBU - Norwegian University of Life Sciences (Norway)
Institutions involved
NA - Cermaq Norway AS (Norway) ,
NA - Grieg Seafood ASA (Norway) ,
NA - SalMar ASA (Norway) ,
VESO - Veterinary Medical Assignment Center AS (Norway) ,
Start year 2022 End year 2025 Funding (€) € 800,500 Website https://www.fhf.no/prosjekter/prosjektbasen/901746/ Summary Outbreaks of infectious salmon anemia (ILA) result in major restrictions for affected facilities. ILA is listed in the EU and in the OIE (World Organization for Animal Health) and Norway is considered the epicenter of the disease. If there is an impression that Norway has reduced control of ILA, it could reduce the export opportunities for the industry. Today's vaccines against ILA are based on inactivated whole virus antigen and provide some protection against mortality, but do not prevent infection or secretion of virus. It must be a goal that herd immunity should not only protect the vaccinated population in a cage, but also prevent the spread of viruses. Good vaccines against ILA will significantly reduce the number of outbreaks, and it is important that Norway is seen as active and credible with cutting-edge research to control the disease. When antigens are produced by the vaccinated individual himself, the cellular response is naturally stimulated. This is achieved with mRNA/DNA vaccines, but not for whole virus vaccines.
Main objective:
Create an effective mRNA vaccine against ILA and develop a general mRNA vaccine technology pipeline for use in fish.
Sub-goals:
• To construct stable mRNA expressing the ILAV hemagglutinin (HE) protein.
• To create lipid nanoparticles that encapsulate mRNA expressing HE.
• To estimate expression of HE protein in cells ( in vitro ) and in salmon ( in vivo ).
• To assess the protective effect in salmon.
• To assess the protective effect against the secretion of viruses.
• To create a general mRNA vaccine platform for fish in a natural way.
Keywords
Genetic;
Fish;
Fish health;
Vaccines development;
Disease;
Salmon;
Marine Region
76
Not associated to marine areas
0
Marine Region Map
